Greenall SA - Search Results

1

Incomplete target neutralization by the anti-cancer antibody rilotumumab.

Greenall SA, Adams TE, Johns TG. Greenall SA, et al. MAbs. 2016;8(2):246-52. doi: 10.1080/19420862.2015.1122149. MAbs. 2016. PMID: 26750997 Free PMC article.

2

Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.

Greenall SA, McKenzie M, Seminova E, Dolezal O, Pearce L, Bentley J, Kuchibhotla M, Chen SC, McDonald KL, Kornblum HI, Endersby R, Adams TE, Johns TG. Greenall SA, et al. Neuro Oncol. 2019 Aug 5;21(8):1016-1027. doi: 10.1093/neuonc/noz073. Neuro Oncol. 2019. PMID: 31002307 Free PMC article.

3

Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.

Greenall SA, Donoghue JF, Gottardo NG, Johns TG, Adams TE. Greenall SA, et al. Oncogene. 2015 Mar 26;34(13):1658-66. doi: 10.1038/onc.2014.106. Epub 2014 Apr 21. Oncogene. 2015. PMID: 24747966

4

EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.

Greenall SA, Donoghue JF, Van Sinderen M, Dubljevic V, Budiman S, Devlin M, Street I, Adams TE, Johns TG. Greenall SA, et al. Oncogene. 2015 Oct 8;34(41):5277-87. doi: 10.1038/onc.2014.448. Epub 2015 Feb 9. Oncogene. 2015. PMID: 25659577

5

Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.

Greenall SA, Lim YC, Mitchell CB, Ensbey KS, Stringer BW, Wilding AL, O'Neill GM, McDonald KL, Gough DJ, Day BW, Johns TG. Greenall SA, et al. Oncogenesis. 2017 May 15;6(5):e336. doi: 10.1038/oncsis.2017.33. Oncogenesis. 2017. PMID: 28504693 Free PMC article.

6

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG. Greenall SA, et al. PLoS One. 2012;7(4):e34658. doi: 10.1371/journal.pone.0034658. Epub 2012 Apr 12. PLoS One. 2012. PMID: 22511956 Free PMC article.

7

Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.

Ymer SI, Greenall SA, Cvrljevic A, Cao DX, Donoghue JF, Epa VC, Scott AM, Adams TE, Johns TG. Ymer SI, et al. Among authors: greenall sa. Cancers (Basel). 2011 Apr 18;3(2):2032-49. doi: 10.3390/cancers3022032. Cancers (Basel). 2011. PMID: 24212795 Free PMC article.

8

EGFRvIII: the promiscuous mutation.

Greenall SA, Johns TG. Greenall SA, et al. Cell Death Discov. 2016 Jul 4;2:16049. doi: 10.1038/cddiscovery.2016.49. eCollection 2016. Cell Death Discov. 2016. PMID: 27551537 Free PMC article. No abstract available.

9

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.

Endersby R, Whitehouse J, Hii H, Greenall SA, Johns TG, Gottardo NG. Endersby R, et al. Among authors: greenall sa. Neoplasia. 2018 May;20(5):432-442. doi: 10.1016/j.neo.2018.02.004. Epub 2018 Mar 22. Neoplasia. 2018. PMID: 29574250 Free PMC article.

10

Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3.

Greenall SA, Donoghue J, Johns TG, Adams TE. Greenall SA, et al. Transl Oncol. 2018 Aug;11(4):971-978. doi: 10.1016/j.tranon.2018.05.011. Epub 2018 Jun 22. Transl Oncol. 2018. PMID: 29933129 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters